538 related articles for article (PubMed ID: 15709205)
1. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
[TBL] [Abstract][Full Text] [Related]
3. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
[TBL] [Abstract][Full Text] [Related]
4. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
[TBL] [Abstract][Full Text] [Related]
5. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
Lam JT; Kanerva A; Bauerschmitz GJ; Takayama K; Suzuki K; Yamamoto M; Bhoola SM; Liu B; Wang M; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
J Gene Med; 2004 Dec; 6(12):1333-42. PubMed ID: 15493039
[TBL] [Abstract][Full Text] [Related]
6. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses.
Hoffmann D; Meyer B; Wildner O
J Gene Med; 2007 Sep; 9(9):764-78. PubMed ID: 17640083
[TBL] [Abstract][Full Text] [Related]
7. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.
Barker SD; Coolidge CJ; Kanerva A; Hakkarainen T; Yamamoto M; Liu B; Rivera AA; Bhoola SM; Barnes MN; Alvarez RD; Curiel DT; Hemminki A
J Gene Med; 2003 Apr; 5(4):300-10. PubMed ID: 12692864
[TBL] [Abstract][Full Text] [Related]
8. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
[TBL] [Abstract][Full Text] [Related]
9. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment.
Davydova J; Le LP; Gavrikova T; Wang M; Krasnykh V; Yamamoto M
Cancer Res; 2004 Jun; 64(12):4319-27. PubMed ID: 15205347
[TBL] [Abstract][Full Text] [Related]
10. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
Maemondo M; Saijo Y; Narumi K; Kikuchi T; Usui K; Tazawa R; Matsumoto K; Nakamura T; Sasaki K; Takahashi M; Niitsu Y; Nukiwa T
Cancer Res; 2004 Jul; 64(13):4611-20. PubMed ID: 15231673
[TBL] [Abstract][Full Text] [Related]
12. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
13. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
14. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.
Stoff-Khalili MA; Rivera AA; Glasgow JN; Le LP; Stoff A; Everts M; Tsuruta Y; Kawakami Y; Bauerschmitz GJ; Mathis JM; Pereboeva L; Seigal GP; Dall P; Curiel DT
Gene Ther; 2005 Dec; 12(23):1696-706. PubMed ID: 16034451
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
16. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
18. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
[TBL] [Abstract][Full Text] [Related]
19. Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication.
Kawakami Y; Li H; Lam JT; Krasnykh V; Curiel DT; Blackwell JL
Cancer Res; 2003 Mar; 63(6):1262-9. PubMed ID: 12649186
[TBL] [Abstract][Full Text] [Related]
20. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma.
Barker SD; Dmitriev IP; Nettelbeck DM; Liu B; Rivera AA; Alvarez RD; Curiel DT; Hemminki A
Gene Ther; 2003 Jul; 10(14):1198-204. PubMed ID: 12833129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
